Apixaban and Skyrizi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Apixaban (apixaban) and Skyrizi (risankizumab-rzaa). Common drug interactions include contusion among females and blood creatinine increased among males.

The phase IV clinical study analyzes what interactions people have when they take Apixaban and Skyrizi. It is created by eHealthMe based on reports of 44 people who take the same drugs from the FDA, and is updated regularly.

What is Apixaban?

Apixaban has active ingredients of apixaban. It is often used in blood clots. eHealthMe is studying from 60,351 Apixaban users. Check the latest studies of Apixaban.

What is Skyrizi?

Skyrizi has active ingredients of risankizumab-rzaa. eHealthMe is studying from 45,385 Skyrizi users. Check the latest studies of Skyrizi.

On Jul, 29, 2026

44 people who take Apixaban and Skyrizi together, and have interactions are studied.

What are the common drug interactions of Apixaban and Skyrizi, by gender? *:

female:

Contusion (a type of hematoma of tissue in which capillaries)
Dehydration (dryness resulting from the removal of water)
Dizziness
Drug hypersensitivity
Dry mouth
Eye disorder
Gastrointestinal pain
Immunosuppression
Injection site bruising
Injection site pain

male:

Blood creatinine increased
Haematocrit decreased
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Pulmonary embolism (blockage of the main artery of the lung)
Coronary artery embolism (blockage of artery of heart)
Diarrhoea
Dyspnoea (difficult or laboured respiration)
Oedema peripheral (superficial swelling)
Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
Base excess increased

What are the common drug interactions of Apixaban and Skyrizi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Cellulitis (infection under the skin)
Erythema (redness of the skin)
Abdominal pain
Pulmonary embolism (blockage of the main artery of the lung)
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
Feeling hot
Folate deficiency (lack of folic acid)
Pain in extremity
Peripheral swelling
Portal vein thrombosis (venous thrombosis affecting the hepatic portal vein)

40-49:

Muscle strain (an injury to a muscle in which the muscle fibres tear)
Pulmonary embolism (blockage of the main artery of the lung)
Tricuspid valve incompetence (inefficient heart valve)

50-59:

Blood creatinine increased
Haematocrit decreased
Haemoglobin decreased
Blood potassium increased
Red blood cell count decreased
Blood urea increased
Blood bicarbonate decreased
C-reactive protein increased
Base excess increased
Carbon dioxide decreased

60+:

Hypervolaemia (abnormally increased volume of blood)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Status epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure)
Asthenia (weakness)
Cardiac failure congestive
Death
Diarrhoea
Plasma cell myeloma (cancer that begins in plasma cells)
Pleural disorder
Pneumonia

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 39 people, 88.64%
Depression: 8 people, 18.18%
Insomnia (sleeplessness): 8 people, 18.18%
Dyslipidaemia (abnormal amount of lipids): 8 people, 18.18%
Portal Hypertension (increase in the blood pressure within a system of veins called the portal venous system): 6 people, 13.64%
High Blood Pressure: 6 people, 13.64%
High Blood Cholesterol: 6 people, 13.64%
Cellulitis (infection under the skin): 5 people, 11.36%
Failure To Thrive (inadequate weight gain and physical growth in children): 5 people, 11.36%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 5 people, 11.36%

* Approximation only. Some reports may have incomplete information.

Do you take Apixaban and Skyrizi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously